Ownership and insider activity for GH Research PLC (GHRS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD).
Price
| Price | $27.75 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | IE |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $498000 | $5.9M | $276.8M | $166.0M | $78.4M | $100.8M | $246.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | $83.1M | $48.5M | $34.5M |
| Receivables | 0 | $6000 | $48000 | $90000 | $178000 | $1.7M | $1.3M |
| Inventory | 0 | 0 | $3.0M | 0 | 0 | 0 | 0 |
| Total Current Assets | $504000 | $5.9M | $279.8M | $168.5M | $164.1M | $154.2M | $286.0M |
| Property, Plant & Equipment | 0 | 0 | $82000 | $97000 | $1.1M | $748000 | $620000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $504000 | $5.9M | $279.9M | $254.4M | $226.3M | $188.3M | $288.2M |
| Accounts Payable | $93000 | $1000 | $883000 | $1.9M | $3.5M | $3.7M | $3.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $104000 | $246000 | $2.7M | $4.5M | $6.7M | $9.0M | $8.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $104000 | $246000 | $2.7M | $4.5M | $7.3M | $9.3M | $8.5M |
| Retained Earnings | -$389000 | -$835000 | -$10.0M | -$32.5M | -$67.9M | -$106.4M | -$154.4M |
| Total Equity | $400000 | $5.7M | $277.2M | $249.8M | $219.0M | $179.0M | $279.7M |
| Total Debt | 0 | 0 | 0 | 0 | $974000 | $624000 | $512000 |
| Net Debt | -$498000 | -$5.9M | -$276.8M | -$166.0M | -$160.6M | -$148.7M | -$280.2M |
| Working Capital | $400000 | $5.7M | $277.1M | $164.0M | $157.4M | $145.3M | $277.6M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 28.70 |
Profitability
| Return on Equity | -20.86% |
| Return on Invested Capital | -19.85% |
| Return on Assets | -16.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABUS · KURA · LENZ · NBTX · PROK · PVLA · RZLT
Explore sector: Healthcare · Biotechnology
More sections of GHRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks